

#6

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s): Haller ) Examiner:  
App. No. 10/004,848 ) Art Unit: **3763**  
Filed: 12/04/2001 )  
Conf. No. **7030** )  
Title: Patients controlled activation device )  
for administration of drug bolus including a )  
time lock-out mechanism. )

Docket No. P-8572.00

**RECEIVED**

**JAN 28 2003**

TECHNOLOGY CENTER R3700

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

The attached information disclosure statement form and references are submitted under 1.97(b)(3) without fee because either the statement is within three months of the filing date of a national applications, before the mailing of a first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. It is respectfully requested that the examiner consider these documents.

This disclosure statement should not be construed as representation that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(a) exists. Some documents may have markings on them, but no significance should be attributed to the markings. It is believed that this disclosure complies with the requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, and the M.P.E.P. § 609. If for some reason the examiner considers

otherwise, it is respectfully requested that the undersigned be called so that any deficiency can be remedied.


Recognizing that Internet communications are not secure, I hereby authorize the USPTO to communicate with me concerning any subject matter of this application by electronic mail at the address below. I understand that a copy of these communications will be made of record in the application file. M.P.E.P. § 502.03.

Respectfully submitted,

Date: 24 JAN 2003  
Medtronic, Inc.  
USPTO Customer No. 27581  
710 Medtronic Parkway (MS-LC340)  
Minneapolis, MN 55432-5604

*Attachment:* Information Disclosure  
Statement Form

  
Eric R. Waldkoetter  
Attorney Reg. No. 36,713  
Located in The Netherlands (ET + 6 hours)  
Office Tel 011 (31-43) 356-6845  
Cell Tel 011 (31) 6 5155-9936  
Office Fax 011 (31-43) 356-6521  
eric.waldkoetter@medtronic.com



Substitute for form 1449A/PTO \*

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

**Complete if Known**

Application Number	10/004,848
Filing Date	12/04/2001
First Named Inventor	Haller
Group Art Unit	3763
Examiner Name	
Attorney Docket Number	P-8572.00

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US- 5,069,668	12/03/1991	Boydman	
		US- 6,010,483	01/04/2000	Spencer	
		US- 4,392,849	07/12/1983	Peter et al.	
		US- 4,731,051	03/15/1988	Fischell	
		US- 6,126,642	10/03/2000	Kriesel et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
		DE 3227518 A1	05/05/1983	Stoffregen, Juegen, Prof, Dr. med		
		WO 97/15339	05/01/1997	Debiotech S.A.		
		DE 10020494 A1	11/02/2000	Medtronic Inc. Minneapolis		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PCT International Search Report, PCT/US/02/09895 (30/08/2002)	

**RECEIVED**


JAN 28 2003

TECHNOLOGY CENTER R3700

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



3763

PTO/SB/21 (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b> <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	10/004,848	
	<b>Filing Date</b>	12/04/2001	
	<b>First Named Inventor</b>	Haller	
	<b>Group Art Unit</b>	3763	
	<b>Examiner Name</b>		
<b>Total Number of Pages in This Submission</b>	16+	<b>Attorney Docket Number</b>	P-8572.00

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks</b> Box Patent Application Commissioner for Patents Washington, D.C. 20231 __ Pages plus references		

RECEIVED  
JAN 28 2003  
TECHNOLOGY CENTER R3/00

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Medtronic, Inc., USPTO Customer No. 27581 Eric R. Waldkoetter, Reg. No. 36,713
Signature	<i>Eric R. Waldkoetter</i> Tel +31 43 356-6045 Fax +31 43 356-6521
Date	24 JAN 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: <input type="text"/>			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.